Please use this identifier to cite or link to this item:
Title: Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer.
Austin Authors: Cheung, Yee-Ming Melody ;Hoermann, Rudolf;Van, Karen;Wu, Damian;Healy, Jenny;Chao, Michael ;White, Shane ;Yeo, Belinda ;Zajac, Jeffrey D ;Grossmann, Mathis 
Affiliation: General Medicine
Medicine (University of Melbourne)
Olivia Newton-John Cancer Wellness and Research Centre
Issue Date: Feb-2023
Date: 2022
Publication information: Clinical endocrinology 2023; 98(2)
Abstract: Aromatase inhibitor (AI) therapy provides oncological benefits in postmenopausal women with oestrogen receptor-positive breast cancer. However, AI treatment has been associated with increased cardiovascular risk. In nonbreast cancer populations, experimentally induced low oestrogen states and natural transition to menopause have been associated with increases in visceral adipose tissue (VAT), a known surrogate marker for cardiometabolic risk. Given that AI treatment blocks oestradiol production, we hypothesized that AI treatment would increase VAT.
DOI: 10.1111/cen.14839
ORCID: 0000-0003-3875-5698
Journal: Clinical Endocrinology
Start page: 190
End page: 201
PubMed URL: 36271726
ISSN: 1365-2265
Type: Journal Article
Subjects: aromatase inhibitor
breast cancer
cardiometabolic risk
visceral adipose tissue
visceral fat
Breast Neoplasms/drug therapy
Aromatase Inhibitors/therapeutic use
Cardiovascular Diseases/chemically induced
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 19, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.